Physician profile
Kathryn E Tloczynski
NPI 1356537328
$2,246.22
in general payments reported to CMS, 2019-2025
18 companies · $565 in 2025
The $565 reported for 2025 was more than what 75% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $389 · 2022: $360 · 2023: $304 · 2024: $629 · 2025: $565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,466 · Education: $30.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,466.33 |
| Education | $30.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $386.85 | 2022-2025 | Ilumya |
| Abbvie INC. | $340.35 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $307.00 | 2021-2022 | |
| Pfizer INC. | $256.79 | 2023-2025 | |
| Almirall LLC | $250.08 | 2021-2025 | Seysara |
| Janssen Biotech, INC. | $163.66 | 2024-2025 | Tremfya |
| Dermavant Sciences, INC. | $131.72 | 2023 | Vtama |
| Genzyme Corporation | $99.18 | 2025 | |
| Vyne Pharmaceuticals INC. | $52.74 | 2021 | |
| Incyte Corporation | $52.36 | 2023-2024 | Opzelura |
| Arcutis Biotherapeutics, INC. | $38.49 | 2024-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $31.36 | 2025 | |
| Leo Pharma INC. | $31.12 | 2025 | Anzupgo |
| Lilly USA, LLC | $30.65 | 2024 | Ebglyss |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $23.95 | 2024 | Cabtreo |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $20.34 | 2025 | Sotyktu |
| Mckesson Medical-Surgical, INC. | $15.00 | 2021 | |
| Organon LLC | $14.58 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Tloczynski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.